Insomnia :: Caffeine more disruptive for daytime sleep
Caffeine has a stronger disruptive effect on daytime, catch-up sleep after a night of sleep deprivation.
Placebo
Neuroma :: Anesiva – orphan drug status for pain drug 4975 to treat interdigital neuroma
Anesiva, Inc. (Nasdaq: ANSV) announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug status to product candidate 4975 for the treatment of a painful condition in the foot known as interdigital neuroma in patients who fail conservative treatments, such as foot pads, NSAID’s (non-steroidal anti-inflammatory drugs) and injections of corticosteroids, that would otherwise require removing or chemically destroying the nerve that causes the pain. Orphan drug designation is granted by the FDA to encourage companies to develop products that treat rare diseases and conditions and includes incentives such as market exclusivity for seven years, tax credits on qualified clinical trial expenses and a waiver of the FDA prescription drug user fees.
Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial
Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.
Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese
Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.
Smoking :: Naltrexone helps women to give up smoking
Adding the opiate blocker naltrexone to the combination of behavioral therapy and nicotine patches boosted smoking cessation rates for women by almost 50 percent when assessed after eight weeks of treatment, but made no difference for men, report researchers from the University of Chicago in the October 2006 issue of the journal Nicotine and Tobacco Research.
Autism :: Risperdal for treatment of irritability associated with autistic disorder
The U.S. Food and Drug Administration (FDA) approved a new use of one of the leading prescription antipsychotic medications, RISPERDAL(R) (risperidone), for the treatment of irritability associated with autistic disorder, including symptoms of aggression, deliberate self-injury, temper tantrums, and quickly changing moods, in children and adolescents aged 5 to 16 years.(1) This is the first time the FDA has approved any medication for use in children and adolescents with autism.
Nutrition :: Researchers look to solve mystery behind egcg and probiotics
When talking about nutrition, EGCG and probiotics are two words that we’ve been hearing a lot about these days. But most consumers don’t know what they are, where they are found and what they do. Some of that mystery was cleared up this week at the 47th Annual Symposia of the American College of Nutrition (ACN) where leading nutrition experts revealed new research about the health benefits of these two ingredients.
Multiple Sclerosis :: Treatment of relapsing-remitting multiple sclerosis
UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II clinical trials next year.
Stress :: Black tea soothes stress
Daily cups of tea can help you recover more quickly from the stresses of everyday life, according to a new study by UCL (University College London) researchers. New scientific evidence shows that black tea has an effect on stress hormone levels in the body.
Multiple Sclerosis :: Fty720 – fingolimod reduces multiple sclerosis symptoms
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.